QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Forecast, Price & News

$49.93
+0.60 (+1.22%)
(As of 09/26/2023 ET)
Compare
Today's Range
$49.49
▼
$50.85
50-Day Range
$46.90
▼
$66.00
52-Week Range
$37.82
▼
$68.63
Volume
332,942 shs
Average Volume
600,984 shs
Market Capitalization
$3.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.21
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
50.6% Upside
$75.21 Price Target
Short Interest
Bearish
6.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Blueprint Medicines in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$501,600 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.06) to ($7.52) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

462nd out of 964 stocks

Pharmaceutical Preparations Industry

198th out of 445 stocks

See Top Rated MarketRank™ Stocks Here

BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

BPMC Price History

BPMC Stock News Headlines

September 23, 2023 | americanbankingnews.com
Zacks Research Weighs in on Blueprint Medicines Co.'s Q1 2024 Earnings (NASDAQ:BPMC)
September 18, 2023 | americanbankingnews.com
Blueprint Medicines Co. (NASDAQ:BPMC) Given Average Recommendation of "Moderate Buy" by Analysts
September 26, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
September 13, 2023 | markets.businessinsider.com
Berenberg Bank Sticks to Their Buy Rating for Blueprint Medicines (BPMC)
September 8, 2023 | finance.yahoo.com
Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?
September 1, 2023 | finance.yahoo.com
Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?
August 3, 2023 | seekingalpha.com
Blueprint Medicines: Rating Downgrade Amid Growth Concerns
August 3, 2023 | markets.businessinsider.com
What 15 Analyst Ratings Have To Say About Blueprint Medicines
September 26, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
August 3, 2023 | msn.com
Blueprint Medicines dips despite Q2 beat
August 3, 2023 | markets.businessinsider.com
Blueprint Medicines (BPMC) Gets a Buy from H.C. Wainwright
August 2, 2023 | finance.yahoo.com
Blueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
August 2, 2023 | finance.yahoo.com
Why Shares of Blueprint Medicines Are Falling Wednesday
August 2, 2023 | seekingalpha.com
Blueprint Medicines Corporation 2023 Q2 - Results - Earnings Call Presentation
August 2, 2023 | finanznachrichten.de
Blueprint Medicines Corporation: Blueprint Medicines Reports Second Quarter 2023 Results
August 2, 2023 | finance.yahoo.com
Blueprint Medicines Reports Second Quarter 2023 Results
July 31, 2023 | msn.com
Wells Fargo Upgrades Blueprint Medicines (BPMC)
July 19, 2023 | finance.yahoo.com
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
July 14, 2023 | msn.com
Morgan Stanley Reiterates Blueprint Medicines (BPMC) Equal-Weight Recommendation
July 5, 2023 | fool.com
Blueprint Medicines (NASDAQ: BPMC)
June 30, 2023 | reuters.com
Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner Blueprint
June 30, 2023 | finance.yahoo.com
UPDATE 1-Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner Blueprint
June 26, 2023 | finance.yahoo.com
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
June 9, 2023 | finance.yahoo.com
Blueprint Medicines (NASDAQ:BPMC) investors are sitting on a loss of 24% if they invested five years ago
June 8, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC) and Relay Therapeutics (RLAY)
June 5, 2023 | msn.com
SVB Leerink Downgrades Blueprint Medicines (BPMC)
June 5, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Blueprint Medicines (BPMC) and Taro Pharmaceutical (TARO)
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Company Calendar

Last Earnings
8/02/2023
Today
9/26/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
CUSIP
N/A
CIK
1597264
Web
www.blueprintmedicines.com
Phone
(617) 374-7580
Fax
N/A
Employees
660
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$75.21
High Stock Price Forecast
$114.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+48.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($9.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-557,520,000.00
Net Margins
-245.62%
Pretax Margin
-244.46%
Return on Equity
-117.88%
Return on Assets
-43.17%

Debt

Debt-to-Equity Ratio
0.39
Current Ratio
4.80
Quick Ratio
4.70

Sales & Book Value

Annual Sales
$204.04 million
Price / Sales
15.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.60 per share
Price / Book
5.87

Miscellaneous

Outstanding Shares
60,670,000
Free Float
58,311,000
Market Cap
$3.06 billion
Optionable
Optionable
Beta
0.74

Social Links

Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Ms. Kathryn Haviland (Age 47)
    Pres, CEO & Director
    Comp: $1.17M
  • Mr. Alexis A. Borisy A.M. (Age 51)
    Co-Founder & Director
    Comp: $50k
  • Mr. Michael Landsittel (Age 51)
    Chief Financial Officer
    Comp: $785.36k
  • Ms. Christina RossiMs. Christina Rossi (Age 46)
    Chief Operating Officer
    Comp: $875.22k
  • Ms. Tracey L. McCain Esq. (Age 55)
    Exec. VP, Chief Legal & Compliance Officer and Sec.
    Comp: $764.9k
  • Dr. Fouad Namouni M.D. (Age 54)
    Pres of R&D
    Comp: $916.4k
  • Ms. Ariel Hurley (Age 49)
    Sr. VP, Fin. & Principal Accounting Officer
  • Dr. Christopher K. Murray Ph.D. (Age 59)
    Sr. VP of Technical Operations and Chief Technical Operations & Quality Officer
  • Dr. Percy H. Carter M.B.A. (Age 52)
    Ph.D., Chief Scientific Officer
  • Jenna Cohen
    Sr. Director & Head of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 sell ratings, 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BPMC shares.
View BPMC analyst ratings or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2023?

12 brokerages have issued 1 year price targets for Blueprint Medicines' shares. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they predict the company's share price to reach $75.21 in the next twelve months. This suggests a possible upside of 48.9% from the stock's current price.
View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2023?

Blueprint Medicines' stock was trading at $43.81 at the start of the year. Since then, BPMC shares have increased by 15.3% and is now trading at $50.51.
View the best growth stocks for 2023 here.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our BPMC earnings forecast.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($2.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.58) by $0.39. The biotechnology company had revenue of $57.60 million for the quarter, compared to analyst estimates of $45.60 million. Blueprint Medicines had a negative net margin of 245.62% and a negative trailing twelve-month return on equity of 117.88%. Blueprint Medicines's revenue was up 57.8% on a year-over-year basis. During the same quarter last year, the business posted ($2.68) EPS.

What ETFs hold Blueprint Medicines' stock?

ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Fidelity Disruptive Medicine ETF (FMED), Harbor Corporate Culture Small Cap ETF (HAPS), BlackRock Future Health ETF (BMED) and Principal Healthcare Innovators ETF (BTEC).

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.77%), State Street Corp (4.13%), Rock Springs Capital Management LP (3.60%), Alliancebernstein L.P. (2.66%), JPMorgan Chase & Co. (2.65%) and William Blair Investment Management LLC (2.43%). Insiders that own company stock include Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain.
View institutional ownership trends.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $50.51.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.06 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.22) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 660 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -